| Literature DB >> 35228593 |
Farida El Gaamouch1,2, Hsiao-Yun Lin1,2, Qian Wang3,4,5, Wei Zhao2, Jiangping Pan2, Kalena Liu1,3, Jean Wong1, Clark Wu1, Chongzhen Yuan1, Haoxiang Cheng3, Weiping Qin2, Ke Hao3, Bin Zhang3,4,5, Jun Wang6,7.
Abstract
Despite national and international efforts for the prevention of metabolic syndrome and its underlying diseases/disorders, its prevalence is still rising, especially in the middle-aged population. In this study, we explore the effect of high fat diet on the development of metabolic syndrome in middle-aged mice and to evaluate the potential benefits of voluntary physical exercise on the periphery as well as brain cognitive function, and to explore the potential mechanisms. We found that metabolic syndrome developed at middle age significantly impairs cognitive function and the impairment is associated with gene dysregulation in metabolic pathways that are largely affecting astrocytes in the brain. Eight-week voluntary wheel running at a frequency of three times a week, not only improves peripheral glucose control but also significantly improves learning and memory. The improvement of cognitive function is associated with restoration of gene expression involved in energy metabolism in the brain. Our study suggests that voluntary physical exercise is beneficial for metabolic syndrome-induced peripheral as well as cognitive dysfunction and can be recommended as therapeutic intervention for metabolic syndrome and associated diseases.Entities:
Mesh:
Year: 2022 PMID: 35228593 PMCID: PMC8885684 DOI: 10.1038/s41598-022-07252-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Scheme of the experimental design and the effect of high fat diet in middle-aged female mice (A) Scheme of the experimental design. (B–E) Five-month high fat diet on body weight and glucose utilization as reflected by (C) IGTT, (D) fasting glucose and (E) post prandial glucose in plasma. Data represents mean ± SEM, n = 8–18 per group.
Figure 2The effect of voluntary wheel-running on periphery glucose and bone health measurements of (A) Body weight, (B) glucose utilization: IGTT, fasting glucose and postprandial glucose in plasma, (C–D) Bone mineral content and bone mineral density, (E–F) Lean and fat mass following two months voluntary physical exercise. Data represents mean ± SEM, n = 8–9 per group.
Figure 3The effect of high fat diet and physical exercise intervention on learning and memory and transcriptional assessment of hippocampus in response to diet and physical exercise. (A) Short-term memory assessed by fear conditioning, % of freezing in the cue test and context test. (B) Long-term memory assessed by fear conditioning, % of freezing in the cue test and context test (C) Heatmap of genes differentially regulated by high fat diet (DIM vs. CTRL) compared with the same genes regulated by physical exercise (DIM-PE vs. DIM). (D) Number of upregulated genes and downregulated genes in DIM mice compared to CRTL mice and top 10 GO enrichment pathway analysis of DEGs regulated by high fat diet. (E) Number of upregulated genes and downregulated genes in DIM-PE mice compared to DIM mice and top 10 GO enrichment pathway analysis of DEGs regulated by PE intervention. (F) Venn diagrams of total number of significantly upregulated and downregulated genes in high fat treated mice with or without PE intervention and top 10 GO enrichment pathway analysis of DEGs regulated by high fat diet and rescued by PE intervention. Data represents mean ± SEM. n = 7–9 per group for (A) and (B).
Blood biochemistry assessment in control, DIM and DIM-PE mice Plasma levels of metabolic syndrome-associated hormones and cytokines measured at the end of the study. Data represents mean ± STDEV, n = 7–9 per group.
| CTRL | DIM | DIM-PE | P (One-way ANOVA) | P (DIM-PE vs. DIM) | |
|---|---|---|---|---|---|
| C-peptide | 441.7 ± 172.1 | 1415.7 ± 593.8 | 1318.9 ± 558.2 | 0.011 | 0.9414 |
| Insulin | 884.7 ± 257.2 | 4456.1 ± 4011.2 | 3575.3 ± 2615.0 | 0.0432 | 0.765 |
| PP | 103.4 ± 57.7 | 46.6 ± 21.4 | 59.0 ± 44.7 | 0.0328 | 0.7952 |
| Leptin | 6819.4 ± 3539.3 | 29,320.1 ± 19,948.3 | 24,788.3 ± 9493.6 | 0.0048 | 0.7222 |
| GLP-1 | 559.0 ± 300.3 | 1141.0 ± 663.2 | 1038.7 ± 503.6 | 0.0003 | 0.889 |
| GIP | 71.1 ± 46.0 | 343.1 ± 357.4 | 349.4 ± 281.0 | 0.0758 | 0.9984 |
| PYY | 132.5 ± 43.3 | 131.1 ± 46.7 | 152.7 ± 56.4 | 0.5932 | 0.5921 |
| Glucagon | 55.3 ± 33.4 | 70.8 ± 32.0 | 115.2 ± 107.2 | 0.6729 | 1 |
| Amylin | 54.6 ± 40.0 | 62.3 ± 42.1 | 58.7 ± 40.9 | 0.8762 | 0.8505 |
| secretin | 54.8 ± 62.0 | 29.8 ± 16.0 | 29.8 ± 21.3 | 0.523 | 0.765 |
| IL-6 | 49.1 ± 43.7 | 210.8 ± 231.0 | 38.5 ± 33.8 | 0.042 | 0.046 |
| TNF-α | 8.7 ± 3.4 | 19.9 ± 9.1 | 20.2 ± 8.9 | 0.0086 | 0.9974 |
| MCP-1 | 54.3 ± 19.7 | 84.3 ± 51.5 | 58.8 ± 33.6 | 0.261 | 0.3266 |
| Cholesterol | 1.6 ± 0.2 | 2.6 ± 0.4 | 2.5 ± 0.5 | < 0.0001 | 0.8755 |
| Triglyceride | 1.7 ± 0.7 | 2.9 ± 0.8 | 2.0 ± 0.5 | 0.004 | 0.0167 |